SH3PXD2B

Across TCGA pan-cancer cohorts, SH3PXD2B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SH3PXD2B data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher SH3PXD2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SH3PXD2B expression acts as an unfavorable survival marker, although some lineages such as UCEC and LIHC show a favorable association.

STAD, BLCA, and UCEC are the cancer types where SH3PXD2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.287	0.673	<.001	34	view →
BLCA	OS	Median	III,IV	0.232	0.585	.037	3	view →
UCEC	DFS	Median	II,III,IV	0.915	0.440	.040	2	view →
LIHC	DFS	Median	All	1.000	0.278	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SH3PXD2B–STAD (OS)

Open the STAD breakdown →